|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.99 USD | +0.02% |
|
-.--% | - |
| 12-15 | Immunome jumps after promising results for its desmoid tumor treatment |  |
| 12-01 | Tyra Bioscience Appoints Bhavesh Ashar as Chief Operating Officer | MT |
Company Valuation: SpringWorks Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,655 | 3,476 | 3,020 | 1,616 | 2,630 | 2,687 |
| Change | - | 109.99% | -13.11% | -46.49% | 62.74% | 2.16% |
| Enterprise Value (EV) 1 | 1,328 | 2,917 | 2,589 | 1,024 | 1,975 | 2,233 |
| Change | - | 119.7% | -11.25% | -60.43% | 92.75% | 13.08% |
| P/E | -10.1x | -68.9x | -17.3x | -5x | -7.09x | -10.4x |
| PBR | 5.14x | 6.27x | 7.16x | 2.9x | 4.28x | 5.59x |
| PEG | - | 1x | -0x | -0.1x | 6.65x | 0.3x |
| Capitalization / Revenue | - | 99,312,098x | - | - | 482,854,888x | 14,023,842x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -22.5x | -63.4x | -15x | -3.66x | -5.78x | -8.13x |
| EV / EBIT | -22.4x | -63x | -14.9x | -3.65x | -5.76x | -8.03x |
| EV / FCF | -46.7x | -181x | -40.8x | -11.6x | -17.4x | -20x |
| FCF Yield | -2.14% | -0.55% | -2.45% | -8.62% | -5.73% | -5% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -3.81 | -1.053 | -3.586 | -5.206 | -5.15 | -3.482 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 35 | - | - | 5.447 | 191.6 |
| EBITDA 1 | -59.05 | -45.98 | -173 | -279.9 | -341.3 | -274.7 |
| EBIT 1 | -59.24 | -46.32 | -173.5 | -280.7 | -343 | -278.1 |
| Net income 1 | -58.31 | -45.57 | -173.9 | -277.4 | -325.1 | -258.1 |
| Net Debt 1 | -327.7 | -559.1 | -431.4 | -591.8 | -655.5 | -454 |
| Reference price 2 | 38.49 | 72.52 | 61.98 | 26.01 | 36.50 | 36.13 |
| Nbr of stocks (in thousands) | 43,006 | 47,931 | 48,727 | 62,137 | 72,058 | 74,365 |
| Announcement Date | 3/12/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/27/24 | 2/20/25 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 3.54B | |
| 16.39x | 3.56x | 9.6x | 0.62% | 64.39B | |
| 27.8x | 5.64x | 16.51x | 0.57% | 56.12B | |
| 33.34x | 11.27x | 21.36x | -.--% | 40.54B | |
| -51.07x | 3.04x | 8.99x | 3.59% | 37.98B | |
| 34.88x | 3.71x | 11.39x | -.--% | 31.89B | |
| -7.78x | 11.08x | -6.75x | -.--% | 26.69B | |
| 16.77x | 3.14x | 9.51x | -.--% | 22.73B | |
| 47.36x | 5.16x | 35.75x | -.--% | 16.66B | |
| 25.75x | 5.35x | 14.4x | -.--% | 16.6B | |
| Average | 15.94x | 5.77x | 13.42x | 0.53% | 31.71B | |
| Weighted average by Cap. | 14.44x | 5.67x | 12.71x | 0.66% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SWTX Stock
- Valuation SpringWorks Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
